https://www.live-feeds.com/feed/argenx-digests-phase-2-celiac-win-for-2-2b-drug-preps-pivotal-runContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/argenx-digests-phase-2-celiac-win-for-2-2b-drug-preps-pivotal-runhttps://www.live-feeds.com/feed/argenx-digests-phase-2-celiac-win-for-2-2b-drug-preps-pivotal-run#u116437Sun, 11 Oct 2026 14:36:17 +0000Argenx shares plunged after the company discontinued a late-stage study of its drug Vyvgart for Sjögren's disease following a futility flag showing the treatment failed to outperform a placebo. Simultaneously, the company reported positive topline results from a Phase 2 trial of its experimental CD122 inhibitor FB102 in celiac disease, where the drug met its primary endpoint by preventing gluten-induced intestinal damage in a 126-patient study. Argenx now plans to advance the $2.2B drug FB102 into Phase 3 development despite the setback for its autoimmune disease candidate.Why it mattersT